Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. provides comprehensive kidney care through a global dialysis and care-delivery network. Company news commonly covers quarterly operating results, revenue per treatment, patient care costs, reimbursement trends, share repurchases and investor conference participation.
Updates also address DaVita's value-based kidney care programs, coordinated care arrangements, and services that support patients across stages and settings of kidney disease, including home support, outpatient dialysis centers, hospitals, skilled nursing facilities and transplantation-related care.
DaVita Kidney Care announced the recognition of 60 nephrology nurses with The DAISY Award during National Nurses Week. This award celebrates the extraordinary care these nurses provide to patients. Each honoree received a personalized certificate, a DAISY Award pin, and a hand-carved sculpture. DaVita, one of the largest kidney care service providers in the U.S., serves over 202,600 patients across 2,827 outpatient dialysis centers. The company is committed to improving patient care through innovative practices and reducing hospitalizations.
DaVita Kidney Care announced the expansion of its home kidney care program with the HomeChoice Claria Automated Peritoneal Dialysis (APD) system, enhanced by Sharesource remote patient monitoring technology from Baxter International. This initiative aims to empower patients to manage kidney failure at home, offering improved connectivity between patients and care teams. Currently, DaVita is utilizing this technology with over 250 patients across the U.S., focusing on enhancing the quality of life for individuals undergoing peritoneal dialysis.
DaVita reported Q1 2021 results showing diluted EPS from continuing operations at $2.09, a 15.5% increase YoY. Consolidated revenues reached $2.820 billion, while operating income was $443 million. Operating cash flow fell to $154 million, and free cash flow was negative at $(17) million, impacted by COVID-19. The company repurchased nearly 3 million shares at an average cost of $109.28. Although the pandemic posed challenges, DaVita successfully vaccinated nearly 75% of its U.S. dialysis patients, enhancing health equity.
Summary not available.
DaVita Inc. (NYSE: DVA) announced a quarterly conference call to discuss its first-quarter results on April 29, 2021, at 5:00 p.m. Eastern Time. The financial results will be released after market close on the same day. Investors can access the call via dial-in or webcast and must provide the password "Earnings" during the call.
DaVita is a leading healthcare provider focused on kidney care, serving over 204,200 patients at 2,816 outpatient dialysis centers in the U.S. It also operates facilities in ten countries, emphasizing patient-centric care models and technological integration.
Blue Cross and Blue Shield of Minnesota has launched a new value-based kidney care program in partnership with VillageHealth, a subsidiary of DaVita. This initiative aims to enhance health outcomes and reduce care costs for members with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). Key elements include coordinated care, early patient outreach, predictive analytics for high-risk individuals, and comprehensive patient education. The program seeks to delay disease progression and improve quality of life for thousands while aiming to decrease hospital admissions by nearly 30%.
DaVita has released its inaugural Diversity & Belonging (D&B) report, outlining its metrics and commitments to fostering a diverse workplace. CEO Javier Rodriguez emphasizes the importance of diversity in enhancing workplace culture and patient connections. The company expanded its D&B program to include health equity and economic mobility in 2020. DaVita aims to create an inclusive environment supporting all individuals, seeking to unlock their full potential. As of December 31, 2020, DaVita served over 204,200 patients through 2,816 outpatient dialysis centers across the U.S.
On March 25, 2021, the Biden administration announced a partnership with dialysis providers, including DaVita, to facilitate COVID-19 vaccinations for dialysis patients and staff. Javier Rodriguez, CEO of DaVita, praised the initiative, emphasizing its importance for high-risk patients and health equity. The program aims to provide vaccines at outpatient dialysis centers, thereby enhancing access and reducing vaccine hesitancy. DaVita, a leader in kidney care services, operates numerous centers across the U.S. and globally, dedicated to improving patient care and outcomes.
On March 23, 2021, Fresenius Medical Care North America (FMCNA) and DaVita Kidney Care announced a collaboration to enhance home dialysis services for patients in the U.S. The partnership includes the provision of NxStage home hemodialysis machines and related technologies to promote home treatment options. This initiative aims to improve quality of life for patients with chronic kidney failure by facilitating greater autonomy in their care. The NxStage systems offer innovative connectivity features to track treatment, aligning with recent Medicare programs to boost home dialysis adoption.
NephroSant has successfully closed a $16 million Series A funding round, led by DaVita Venture Group with participation from DigitalDx Ventures and others. This funding will support the launch of Qsant™, a non-invasive urine test for detecting kidney transplant rejection. Current rejection rates stand at 40%. Qsant™ simplifies the testing process by using a single urine sample, enhancing patient convenience and safety, especially amid the COVID-19 pandemic. The investment highlights the commitment to improve kidney health and patient outcomes.